Morning Star | Ten Qiming Venture Partners Portfolio Companies Win BIOCHINA Awards
The awards aim to uncover innovative forces in the biopharmaceutical industry.
At BIOCHINA 2025 (the 10th edition), the BIOCHINA Awards winners were announced. The awards aim to spotlight innovative forces in the biopharmaceutical industry.
Qiming Venture Partners portfolio companies MediLink Therapeutics, Leads Biolabs, Hope Medicine, and Luoqi Biotech were named to the 2024 Innovation Breakthrough list. ZhenGe Biologics, Insail, Crown Bioscience, BioLink, Medicilon, and PRCXI were named to the 2024 Supplier of the Year list.
MediLink Therapeutics, Leads Biolabs
Hope Medicine, Luoqi Biotech
Named to
2024 Innovation Breakthrough list
ZhenGe Biologics, Insail, Crown Bioscience
BioLink, Medicilon, PRCXI
Named to
2024 Supplier of the Year list
- 2024 Innovation Breakthrough list
This list recognizes companies actively exploring new paths, refining their technological moats, keeping patients at the center, and achieving genuine breakthroughs.
- 2024 Supplier of the Year list
These companies serve as the backbone of industrial development and critical pillars supporting the industry forward — indispensable players in the pharmaceutical supply chain.
In 2024, full-chain commercialization became the prevailing trend in biopharma. The BD wave showed no signs of cooling, NewCo-based global expansion became established practice, M&A activity surged, biotech pipeline partnerships flourished in diverse forms, and pharmaceutical companies carved out entirely new development paths.
Source | EBiomedicine
Past Coverage
Qiming Stars | Over 10 Qiming Venture Partners Portfolio Companies Honored with BIOCHINA Awards
Qiming Honors | Qiming Venture Partners and Portfolio Company Female Leaders Receive Over 10 Awards
Qiming Venture Partners was founded in 2006. The firm currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since its inception, Qiming has focused on investing in early and growth-stage companies in Technology and Consumer (T&C) and Healthcare sectors.
To date, Qiming Venture Partners has invested in over 580 high-growth innovative companies. More than 210 of these have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A and other means. Over 80 portfolio companies have become recognized unicorns or super-unicorns.
Many Qiming portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), APT Medical (688617.SH), Sanyou Medical (688085.SH), AmoyDx (300685.SZ), Berry Genomics (000710.SZ), Sinocelltech (688520.SH), Yuanxin Technology, Caidya, Belief BioMed, and Biren Technology.